Clinical Characteristic of patients with Essential Thrombocythemia (ET) and heparin induced thrombocytopenia according to JAK2 (V617F) Mutation.
| ET JAK2 mutation positive |
ET JAK2 mutation negative |
P value | |
|---|---|---|---|
| N | 58 (100%) | 50 (100%) | |
| Male/Female | 27/31 | 27/23 | ns |
| Median age (Years/range) | 41(16-65) | 43 (18-67) | ns |
| Median Follow up (Years) | 4 (1-5) | 4(1-5) | ns |
| Low molecular weight heparin | 46 (79%) | 37 (74%) | ns |
| MPL mutation | Not detected | 2 (4%) | na |
| CALR mutation | Not detected | 10 (20%) | na |
| Triple negative patient | 7 (14%) | na | |
| Prior Heparin treatment | 11 (19%) | 9 (18%) | ns |
| Cytoreduction with Hydroxyurea | 16 (27.5%) | 10 (20%) | ns |
| Cytoreduction with Interferon | 1 (1.7%) | 1 (2%) | ns |
| Reason for heparin treatment | |||
| Cranial sinus Thrombosis | 10 (17,2 %) | 8 (16%) | ns |
| Coronary artery Disease | 4 (6.9%) | 2 (4%) | ns |
| Mesenteric and portal vein thrombosis | 4 (6.9%) | 2 (4%9 | ns |
| Surgery Prophylaxis | 22 (38%) | 25 (50%) | ns |
| Budd Chiari Syndrome | 5 (8.6 %) | 3 (6%) | ns |
| Deep vein thrombosis | 7(12%) | 4 (8%) | ns |
| Initial platelet count (x 10 9/L) mean | 1076 | 980 | p< 0.001 |
| Total | 10 (17.2%) | 2 (4%) | P=0.029 |
| New neurological signs | 2 of 10 (20%) | 1 of 2 | |
| Arterial limb ischemia | 1 of 10 (10%) | ||
| Sinus vein thrombosis | 1 of 10 (10%) | ||
| Pulmonary embolism | 1 of 10 (10%) | ||
| Central vein thrombosis | 2 of 10 (20%) | ||
| Unusualsplanchnic vein thrombosis | 3 of 10 (30%) | 1 of 2 | |
| Low Molecular weight heparin while thrombosis | 7 | 2 |
Ns: not significant, na: not applicable